Soluble immune response suppressor (SIRS), a lymphokine that suppresses antibody production and delayed type hypersensitivity in vivo, has been detected in urine and serum from certain patients with nephrotic syndrome. In the present paper, the relationship between SIRS production and nephrotic syndrome is further characterized. A striking correlation was found between detection of SIRS and the presence of steroid-responsive nephrotic syndrome (SRNS). A potential mechanism of SIRS production in SRNS patients was identified, in that (a) lymphocytes from patients produced SIRS without requiring activation by exogenous agents, and (b) incubation of normal lymphocytes with serum from patients activated the cells to secrete SIRS in culture. Although SIRS disappears rapidly from urine or serum after initiation of corticosteroid therapy, hydrocortisone (1O-'-1O-M) did not block secretion of SIRS by activated suppressor cells. It did, however, inhibit in vitro activation of lymphocytes to produce SIRS by concanavalin A, interferon, or SRNS patient serum. The association of suppressor cell activation with SRNS and the sensitivity of both to steroids suggest that the pathogeneses of albuminuria and SIRS production are related.
Introduction
Patients with nephrotic syndrome frequently manifest suppressed clinical and experimental immune responsiveness. We have previously reported identification of the lymphokine, soluble immune response suppressor (SIRS)' in urine and serum ofchildren with minimal change nephrotic syndrome (MCNS) and other forms of nephrotic syndrome classically associated with an immune pathogenesis (1) . This protein, which is produced by concanavalin A (Con A) or interferon (IFN)-activated suppressor T lymphocytes in vitro, has been purified to homogeneity and has a molecular weight of 15,000 D. It inhibits antibody production and tumor cell division in vitro (2) . Recent data indicate that SIRS also suppresses in vivo antibody production and delayed type hypersensitivity in mice (3) , suggesting that SIRS activity may account for the immune suppression observed in some nephrotic patients. In our previous report SIRS activity was not found in patients who were nephrotic because of focal segmental glomerulosclerosis or congenital nephrotic syndrome, or in nonnephrotic patients with acute glomerulonephritis. Further, SIRS disappeared from urine ofchildren with MCNS soon after initiation of corticosteroid therapy but before entry of the patient into remission. In patients with nephrosis resulting from glomerulonephritis who experienced normalization of serum albumin concentration after steroid therapy, SIRS excretion ceased despite continued signs of renal inflammation such as hypocomplementemia and abnormal urinary sediment. Production of SIRS thus was associated with certain causes of nephrotic syndrome and appeared to be inhibited by steroid therapy (1) .
These data raise questions concerning the source of SIRS in nephrotic patients, the factors that determine the presence of SIRS production in certain cases, and the relationship between the efficacy ofsteroid therapy for nephrosis and the disappearance of SIRS from patient urine. Results presented here show that lymphocytes are at least one source of SIRS in patients with steroid-responsive nephrotic syndrome (SRNS) and that hydrocortisone inhibits activation of lymphocytes to produce SIRS by Con A, IFNs or a serum factor also present in patients with SRNS. All patients tested who responded to steroid therapy showed urine or serum SIRS activity. The striking correlation between SRNS and SIRS production, and the sensitivity ofboth albuminuria and SIRS production to steroids, suggest a relationship between SIRS production and the pathogenesis of SRNS.
Methods
Unless otherwise specified all chemicals were reagent grade and purchased from commercial sources.
Patient population. Patients In vitro activation oflymphocytes to produce SIRS. Peripheral blood mononuclear cells (PBMC) were obtained from patients and healthy volunteers by venipuncture and withdrawal of heparinized whole blood. The sample was diluted 1:1 with Hanks' balanced salt solution and centrifuged through a Ficoll/sodium diatrizoate gradient according to the method of Boyum (5) . After washing, 3 X 106 PBMC were suspended in 1.5 ml RPMI 1640 medium supplemented with penicillin/streptomycin, glutamine, nonessential amino acids, and 10% fetal calf serum (lot 58101, Reheis Chemical Co.,). Con A or IFN was added to cultures, which were then incubated in sterile, 12-ml, round-bottom, plastic culture tubes for 24 h in 5% humidified CO2 in air at 370C. The cells were washed twice with Hanks' solution and resuspended in fresh culture medium for an additional 24 h. After centrifugation to remove the PBMC, culture supernatant was aspirated by pasteur pipette. Supernatant fluids of PBMC cultures prepared in this manner contain SIRS, as demonstrated by several functional and physical criteria (1, 6) .
Assayfor SIRS activity. Human splenocytes were obtained aseptically from cadaver kidney transplant donors at the time of organ harvest, processed as described previously (6) , and preserved frozen in liquid nitrogen until use (1). Urine, serum, or lymphocyte supernatant was added to 2 X 106 human splenocytes cultured in 1 ml supplemented RPMI 1640 medium with 5 Ag pokeweed mitogen for 6 d in humidified 5% CO2 in air. These cultures were assayed for polyclonal IgM production by a slide modification of the Jerne hemolytic plaque-forming cell (PFC) assay (7) as described previously (8); PBMC cultures may be similarly assayed for PFC response in these types of experiments. Fluids that caused >50% suppression of PFC response compared with the response ofcontrol cultures were considered to show significant suppressive activity. Suppression was confirmed to be SIRS-mediated by the ability of monoclonal anti-SIRS antibody coupled to Sepharose 4B (Sigma Chemical Co., St. Louis, MO) to absorb suppressive activity from solution (9) . Separation of T cell subpopulations. Monoclonal antibodies to human helper/inducer cell (OKT4) and suppressor/cytotoxic cell (OKT8) surface antigens were used to isolate these two populations as described previously (6) . Briefly, 2 X I07 PBMC in 2 ml RPMI 1640 medium were incubated with 10 ,l monoclonal antibody reconstituted according to the package insert (Ortho-mune, Ortho Diagnostic Systems, Raritan, NJ) at 40C for 45 min, washed, and resuspended in rabbit complement at 37°C for 45 min. Alternatively, antibody-treated cells were layered onto 100 X 15 mm sterile plastic culture dishes (Fisher Scientific Co., Pittsburgh, PA) coated with goat anti-mouse IgG (0.75 gg/ml). Nonadherent cells were obtained after the plates were gently swirled, and adherent cells were then removed by vigorous pipetting. After treatment, cells were washed and resuspended at 2 X 106 cells/ml in culture medium.
Results
Serum SIRS activity in nephrotic syndrome. We previously reported that four children with urinary excretion of SIRS also had SIRS activity in their serum (1) . Further investigation has confirmed that virtually every adult and pediatric patient with SIRS activity had SIRS in both urine and serum. In the single exception, SIRS was present in serum obtained before initiation of steroid therapy, but no urine was obtained for 24 h after initiation of treatment; SIRS activity was not found in a subsequent urine specimen. Fig. 1 (10) , which has inhibitory effects on in vitro immune responses.
Disappearance ofSIRS activity from serum with treatment. SIRS disappears from urine shortly after initiation of steroid therapy. To determine whether SIRS also disappears from serum during treatment, sera were obtained in a serial fashion during the treatment course from four patients in relapse. In each case, assay for SIRS activity showed results similar to those for the patient with MCNS described in Table I . SIRS was present before therapy, but not thereafter. The patient entered remission on day 8 . These results show that, as with urine SIRS, serum SIRS (Table IV) . PBMC from all patients were found to secrete SIRS spontaneously. In contrast, PBMC from six healthy volunteers did not secrete SIRS. Further, PBMC from three patients with steroid-unresponsive nephrosis did not secrete SIRS. All subjects in the control and steroid-unresponsive groups showed normal SIRS production when PBMC were stimulated with Con A. While the number of patients evaluated is small, the data indicate that serum SIRS activity in patients with SRNS is associated with the presence of circulating lymphocytes activated to secrete SIRS, and suggest that this lymphocyte activity is a source of serum SIRS.
Activation ofnormal lymphocytes to produce SIRS by SRNS patient serum. These data suggested that suppressor cells were activated in vivo to produce SIRS. The observation in previous experiments that SRNS patient serum continued to have some suppressive activity after absorption with anti-SIRS antibody (Fig. 1) raised the possibility that an agent in patient serum that was antigenically distinct from SIRS could activate lymphocytes to produce SIRS. To test this hypothesis, PBMC obtained from normal donors were incubated for 24 h with patient serum, washed, and cultured for an additional 24 h. The culture supernatants were then tested for SIRS activity. Fig. 3 shows the results of one experiment. Serum from a normal donor did not induce significant suppressive activity. However, PBMC incu- Effect ofhydrocortisone on secretion ofSIRS byPBMCfrom SRNSpatients. SIRS was previously shown to disappear rapidly from urine or serum of patients with SRNS after initiation of steroid therapy (1) . To determine the effect of steroids on secretion of SIRS by patient lymphocytes, hydrocortisone was added to cultures of PBMC from four patients with SRNS at doses (I0-6'-I7 M) that approximate high therapeutic concentrations in patient plasma (13) . Fig. 4 Effect ofhydrocortisone on suppression by agents that activate the SIRSpathway. These findings did not explain the relationship of treatment to the disappearance of SIRS activity observed in patients. To further investigate the role corticosteroids may play in regulating SIRS production, a series of experiments was undertaken examining the effect ofhydrocortisone on in vitro SIRSmediated suppression. Agents such as anti-SIRS antibodies, which block SIRS activity, also block suppression by Con A or IFN (3, 6, 9, 14) and by suppressor cells activated by these agents (6) . This suggests that suppression of PFC responses by Con A or IFN is mediated primarily through the SIRS pathway. (16) and specific antibody titers (17) , and suppression of delayed-type hypersensitivity to a variety of antigens ( 18) . Increased suppressor cell activity ( 19) and suppressive activity of patient sera (20) In the present paper, serum SIRS activity was found in the same spectrum of diseases that manifest urinary excretion of SIRS. Serum SIRS, like urine SIRS, disappeared with steroid therapy. This finding is consistent with the hypothesis that SIRS mediates immune suppression in these patients, since normalization of immune responses has been reported to occur with induction of remission in MCNS (18) . Cultured PBMC from patients with SRNS secreted SIRS without requiring activation by exogenous agents. SIRS secreted by patient PBMC in vitro was antigenically and functionally similar to the factor previously identified in patient serum and urine. Further, all patients with urine or serum SIRS activity who were tested, and only these patients, had circulating lymphocytes that were activated to produce SIRS. These data suggest that. activated suppressor cells may be the source of serum and urine SIRS activity. However, it is conceivable that other body tissues may also contribute to the systemic presence of SIRS.
Inhibition of responses by patient sera or by lymphocyte supernatant fluids was not total, with a plateau ranging between 50 and 80 percent suppression in different experiments. By contrast, suppression of murine plaque-forming cell responses by purified murine SIRS is more complete. Although the cause of this phenomenon is not known, experimental conditions that could affect the degree of suppression obtained include competing effects of other regulatory agents present in the sera or supernatants, the fact that responses are stimulated with mitogen in the human assay but with antigen in the murine assay, and differences in sensitivity to SIRS of human as opposed to murine splenocytes. The significance of the plateau of suppression seen in these experiments is uncertain.
The observation that SIRS activity disappears from serum after initiation of treatment also indicates that the previously reported disappearance ofSIRS from patient urine may not result solely from changes in glomerular permeability. Treatment with corticosteroids appears to inhibit production of SIRS. Steroids do not prevent release of SIRS by activated lymphocytes, since secretion of SIRS by PBMC from patients with SRNS was not inhibited by hydrocortisone added to cultures. Instead, these drugs appear to prevent stimulation ofsuppressor cells to release SIRS. In patients with SRNS, steroid therapy may thus cause SIRS to disappear by blocking further activation of suppressor cells in vivo. The rapid disappearance ofSIRS from body fluids, and the limited period ofSIRS secretion by patient lymphocytes in vitro, suggest that the duration ofSIRS production by activated suppressor cells in vivo is also brief. To produce the consistent levels ofSIRS found in untreated patients with SRNS this would require that suppressor cells are continually being activated. OKT8' lymphocytes from normal donors were activated to produce SIRS by incubation with serum from patienits with SRNS, suggesting that a circulating factor may account for in vivo activation of suppressor cells in these patients.
The data obtained in screening nephrotic patients for SIRS production identify a group of patients characterized by remission of nephrotic symptoms after steroid therapy. All patients with SRNS produced SIRS by a mechanism that also appears
